About this episode
Speaker 1: (01:20)
Today we want to talk about the MDM2 gene amplification assay. Can you give us a little bit of an overview of that test?
Speaker 1: (02:16)
Is there a certain subset of patients that should have this testing, and when should it be performed on those patients?
Speaker 1: (02:50)
So for those patients then, are there any other alternative test options that are available for them, or how else might these patients be diagnosed, and how does this specific task compare with the other options out there?
Speaker 1: (03:59)
It sounds like this test is going to be used primarily for a diagnosis in this specific case. Then how does that impact patient care?
Speaker 1: (04:50)
Can you explain this in a way that a patient would understand why this test would be done?
Resources
MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Unique Assays Advance Care of Complex Autoimmune Skin Conditions
Answers from the Lab
Digital Advances: What’s Next for Clinical Diagnostics?
Answers from the Lab
Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes
Answers from the Lab
Breakthrough Test Enhances Peripheral Neuropathy Care and Research
Answers from the Lab